Anne Wojcicki Returns to Lead 23andMe
- Anne Wojcicki, co-founder and former CEO of 23andMe, is poised to buy back the genome testing company through her nonprofit, TTAM Research Institute.
- TTAM research institute will acquire substantially all of 23andMe's assets, according to a press release issued Friday.
- 23andMe, once valued at approximately $6 billion, gained prominence for its at-home genome testing kits.
Anne Wojcicki is set to reclaim her role at 23andMe through a $305 million acquisition via TTAM Research Institute. This pivotal deal, occurring after the company’s Chapter 11 bankruptcy filing, signals a major shift in the genomics landscape. 23andMe, famous for its at-home DNA testing services, faced profitability challenges and a significant data breach; these are the primarykeyword. Following Wojcicki’s unexpected offer, TTAM will acquire the majority of 23andMe’s assets. The secondarykeyword,consumer privacy,is also a focus,with TTAM committing to enhanced consumer protection measures,including a privacy advisory board.Read more news like this on news Directory 3. The acquisition’s finalization is imminent. Discover what’s next for 23andMe and its future in personalized healthcare.
Anne Wojcicki to regain 23andMe Role in $305M Deal
Anne Wojcicki, co-founder and former CEO of 23andMe, is poised to buy back the genome testing company through her nonprofit, TTAM Research Institute. The agreement, valued at $305 million, comes after 23andMe filed for Chapter 11 bankruptcy protection earlier this year.
TTAM research institute will acquire substantially all of 23andMe’s assets, according to a press release issued Friday. This agreement follows an earlier bid from Regeneron Pharmaceuticals, a New York-based biotech firm, which offered $256 million for the company last month. Wojcicki made an unsolicited offer earlier in June, leading to a final round of bidding between TTAM and regeneron.
23andMe, once valued at approximately $6 billion, gained prominence for its at-home genome testing kits. However, the company has struggled to achieve profitability and faced a significant data breach in 2023. Last year, 23andMe settled a lawsuit related to the breach for $30 million. Wojcicki stepped down as CEO when the company declared bankruptcy in March.
TTAM has pledged to uphold 23andMe’s privacy policies and adhere to applicable laws.The institute has also committed to implementing additional consumer protections and privacy safeguards, including the establishment of a consumer privacy advisory board within 90 days of the deal’s closing. The transaction remains subject to court approval and is expected to be finalized in the coming weeks.
What’s next
The acquisition by TTAM research Institute is expected to bring renewed focus on consumer data protection and innovation in personalized healthcare,potentially reshaping 23andMe’s future role in the industry.